Author: Zhu Hanbin Lin Wei Yin CEREALS Date: 2018-09-19 Adoptive reinfusion of silenced NKILA T cells showed efficacy in a preclinical PDX model. The reporter learned from Sun Yat-sen Memorial Hospital of Sun Yat-Sen University that the team of Professor Song Erwei and Su Shicheng discovered that the long non-coding RNA NKILA can induce tumor-specific T cells to induce apoptosis, so that they can not attack the tumor. Research suggests that NKILA in T cells can be knocked out in vitro, thus ensuring the "firepower" of T cells reinfused into the body and enhancing the effect of immunotherapy. Related research was published online in the journal Nature? Immunology on September 17. Immunotherapy was named the top ten scientific breakthrough by Science magazine in 2013 and 2017. Especially in the treatment of lymphoma, melanoma, etc., the effect of immunotherapy is remarkable. However, for solid tumors such as breast cancer, the efficacy of immunotherapy is still weak, which indicates that there are still many unknown mechanisms that need further exploration. The team of Professor Song Erwei and Professor Su Shicheng found that the tumor would “inducate†tumor-specific T cells to “rememberâ€. They found a key role "long non-coding RNA NKILA". When T cells are quiet and have not yet been activated, NKILA is also quiet and in a low-expression state; however, when T cells are busy, NKILA also begins to express a large amount. An important "life-and-death pathway" - the NF-é—Ž pathway, when activated, T cells can resist the attack of tumor cells, thereby fighting tumors. The researchers found that once NGILA is expressed in a large amount, it will inhibit the NF-é—Ž pathway, and the "firepower" of T cells will be greatly reduced, and the tumor cells will be "arrogant". The research team modified T cells in vitro, silenced the expression of NKILA, and then returned T cells to a mouse model of breast cancer, and the NF-é—Ž pathway remained activated. They found that as a result, the number of T cells in the tumor increased significantly, the number of tumor cells killed was increased, and the tumor was significantly reduced. "Based on the results of previous studies, we will knock out TKILA from T cells in vitro and then transfer T cells to tumor patients. We are confident that T cells can better concentrate firepower on tumor cells." Song Erwei said, Compared with tumor cell gene therapy, this method is to modify cells in vitro, which is more reliable and safe. Song Erwei said that currently relying on the platform of Sun Yat-sen Memorial Hospital Immunotherapy Center of Sun Yat-sen University, they plan to conduct Phase I clinical research, which is a preliminary evaluation of clinical pharmacology and human safety evaluation. Related papers: https:// Source: Science Network Foam Dressing,Foam Gauze,Silicone Foam Dressing,Foam Dressing For Pressure Ulcer Roosin Medical Co.,Ltd , https://www.roosinmedical.com